辛伐他汀治疗老年冠心病的疗效及安全性临床研究被引量：6

The Study of the Clinical Efficacy and Safety of Simvastatin in Elderly Coronary Heart Disease

下载PDF

导出

摘要目的:不同剂量他汀类药对老年冠心病患者血脂及血清C-反应蛋白(CRP)浓度的影响。方法:将65例老年稳定性冠心病伴高脂血症患者随机分为低剂量治疗组(n=37)和高剂量治疗组(n=28),低剂量治疗组口服辛伐他汀20 mg/d,高剂量治疗组口服辛伐他汀40 mg/d;疗程均为6周。结果:疗程结束后两组血脂指标(TC、TGL、DL-C)及CRP均较治疗前降低(P<0.05),两组间结果差异无显著性意义(P>0.05)。两组均无不良反应发生。结论:他汀类药对老年冠心病患者也具有良好的降脂效应,且能有效降低患者的CRP,安全性亦好。 Objective：To study the influence of the different doses of simvastatin on blood lipid and C-reactive protein in elderly coronary heart disease. Methods： 65 elderly patients with stable cor onary heart disease accompanied with hyperlipidemia were divided into low dose group （oral 20mg/d simvastatin） and high dose group （oral 40mg/d simvastatin）. All patients were treated for 6 weeks and their blood lipid and blood CRP were measured and analyzed with statistics before and after treatment. Results： After 6 weeks treatment, the plasma levels of TC, TG, LDL-C and CRP were significantly decreased （P〈0.05） in both groups. HDL-C was significantly increased （P〈0.05） in the high dose group. Conclusion. The different doses of simvastatin can reduce the blood lipid and CRP safely in elderly patients with stable coronary heart disease with hyperlipidemia.

作者蒙应东

机构地区茂名市人民医院老年病科

出处《实用临床医学（江西）》 CAS 2006年第2期17-18,25,共3页 Practical Clinical Medicine

关键词他汀类药血脂 C-反应蛋白老年冠心病 simvastatin blood lipid C-reactive protein elderly coronary heart disease

分类号 R963 [医药卫生—微生物与生化药学] R541.4 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献10

1赵水平.冠心病整体防治中他汀类药物的重要地位[J].中华心血管病杂志,2004,32(4):379-381. 被引量：159
2王春明,包斐然.不同剂量辛伐他汀对冠心病患者的调脂疗效观察[J].心脑血管病防治,2005,5(1):24-26. 被引量：22
3Pastemak R C,Smith S C,Rairey-Merz C N,et al.ACC/AHA/NAL/BI Clinical Advisory on the Use and Safety of Statins[J].Circulation,2002,106(8) :1 024-1 028.
4熊瑛,黎艳,刘迪,程良玉,韩爱玲,陈广兮,卢钰.辛伐他汀对冠心病患者C-反应蛋白的影响[J].医药导报,2005,24(3):192-193. 被引量：5
5Robbbie L A,Booth N A,Brown P A J,et al.Inhibitor of Ibbrinolyi are Elevated in Atttheroclerotic Plaque[J].Arrteriocler Thromb Vac Biol,1996,16(1):539.
6Chomiki N,Henry M,Alessi M C,et al.Plassminogen Activatel Walls[J].Thromb Haemosstas,1994,722(1) :44.
7Weber C,Eel W,Weber K S C,et al.HMG-CoA Reductase Inhibitors Decrease CD11b Expression and CD11b-dependent Adhetion of Monocytes to Endothelium and Reduce Increased Adhesives of Monocytes Isolated from Patients with Hypercholesterolemia[J].J Am Coll Cardiol,1997,30 (5):1 212- 1217.
8黄海英,李伟,周广耀.辛伐他汀对高胆固醇血症小鼠血管内皮粘附单核细胞的抑制作用[J].中国新药与临床杂志,2002,21(9):518-520. 被引量：9
9Bellosta S,Via D,Canavesi M,et al.HMG-CoA Reductase Inhibitors Reduce MMP-9 Secretion by Macrophages[J].Arterioscler Thromb Vasc Biol,1998,18(11):1 671-1 678.
10周明术,温先勇,杭永伦.急性时相反应蛋白在冠心病病变中的变化探讨[J].医学理论与实践,2005,18(7):751-752. 被引量：8

二级参考文献15

1Benjamin D H, Joseph B M, John F C, et al. Stain therapy interacts with cytomegalovirus seropositivity and high c-reactive protein in reducing mortality among patients with angiographically significant coronary disease[J]. Circulation,2003,107( 1 ) :258 -263.
2Zee R, Ridker P M. Polymorphism in the human C-reactive protein (CRP) gene, plasma concertrations of CRP, and the risk of future arterial thrombosis[J]. Atherosclerosis, 2002,162( 1 ) :217 - 219.
3Magadle R, Weiner P, Beckerman M, et al. C-reactive protein and chest pain[J]. Clin Cardiol,2002,25(2) :456 -459.
4Paul M R, Nader R P,Susan P L Rapid reduction in c-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia[J]. Circulation,2001,103 (4) :1191 - 1193.
5Filippo C, Glaudia M, Gaetano A L, et al. Inflammatory predictors of mortality in the scandinavian simvastatin survival study [J]. Clin Cardiol, 2002,25(2) :461 -466.
6Fryer RH. Schwobe EP, Woods ML, et al. Chlamydia species infect human vascular endothelial cell and induce procoagulant activity. J Invest Med, 1997,45:168.
7Kuller LH, Tracy RP, Shaten J, et al. Relation of C-reactive protein and coronary heart disease in the MREIT neated casecontrol study-multiple risk factor intervention trial. Am J Epidemiol,1996,144(6):537-547.
8Scandinavian Sinvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease:The Scandinavian Sinvastatin Survival Study(4S). Lancet,1994,344:1383-1389.
9Heart protection study collaborative group. MRC/BHF Heart protection study of cholesterol lowering with simvastatin in 20536 high risk individuals:a randomized placebo-controlled trial Lancet,2002,360:7-22.
10Expert Panel on Detection, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Evaluation program(NCEP) Expert Panel on Detection, Evalution, and Treatment of High Blood Cholesterol (Adults Treatment Panel Ⅲ). JAMA,2001,285:2486-2497.